Browsed by
Tag: Positive

Jets coronavirus positive test: Cardinals still traveling to N.J. ahead of Sunday’s scheduled game

Jets coronavirus positive test: Cardinals still traveling to N.J. ahead of Sunday’s scheduled game

The status of Sunday’s game between the New York Jets and Arizona Cardinals is still up in the air after the Jets sent players and coaches home on Friday following a presumed positive coronavirus test of one player.

But the Cardinals are still operating as if everything is business as usual, according to head coach Kliff Kingsbury, and the team still plans to travel to New Jersey on Friday.

The NFL hasn’t made any decisions about Sunday’s Week 5 contest between the two teams. The Jets made all meeting and workouts virtual on Friday after one player had the presumed positive test for COVID-19. The team was waiting for retesting of the player before making any other decisions.

The league has already shifted two games this week due to coronavirus concerns. The Denver Broncos and New England Patriots will play on Monday instead of Sunday following positive tests by the Pats earlier in the week.

The Tennessee Titans and Buffalo Bills also had their Sunday game moved to Tuesday. The Titans have been dealing with an outbreak that also forced the NFL to postpone a Week 4 game between the Pittsburgh Steelers and Titans to later in the season.

The Jets and Cardinals don’t share bye weeks — the Cardinals are slated to be off in Week 8, and the Jets follow in Week 11 — so if the league is forced to push the game beyond Monday or Tuesday, rescheduling would a little bit more complicated.

Thank you for relying on us to provide the journalism you can trust. Please consider supporting NJ.com with a subscription.

Chris Ryan may be reached at cryan@njadvancemedia.com. Follow him on Twitter @ChrisRyan_NJ. Tell us your coronavirus story or send a tip here

Source Article Read the rest

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis

VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. Psoriasis is a chronic inflammatory skin disease often linked to depression and a decreased quality of life. The global psoriasis treatment market is projected to reach USD $37 billion by 2026. These results come on the heels of a successful preclinical study in atopic dermatitis earlier this year using the same drug.

In the trial, we observed significant inhibitory effects in a dose dependent manner in all concentration ranges tested. Used as a positive control, Dermavant Sciences’ psoriasis drug tapinarof also showed significant antipsoriatic activity in a preclinical trial using the same mouse model. Our drug showed comparable inhibitory effects to tapinarof over a similar range of concentrations. Derm-Biome’s compound inhibits pro-inflammatory cytokine production, it up-regulates anti-inflammatory mediators including interferons and other anti-inflammatory cytokines, and enhances expression of proteins key to maintaining an effective skin barrier. The compound also promotes skin microbiome diversity by inhibiting the growth of pathogenic bacteria, including staph and C. acnes. 

Dr. Youwen Zhou, Professor in the Department of Dermatology and Skin Science, University of British Columbia: “My group ran both the psoriasis and atopic dermatitis trials for Derm-Biome using well established mouse models that I find accurately mimic these human diseases. I have also used these mouse models for other investigational compounds and FDA approved drugs. The Derm-Biome compound blocked the development of psoriasis and atopic dermatitis in a dose dependent manner, both in terms of inflammation scores and in inhibition of the inflammatory mediators of these diseases. It is a compound with promising potential

Read the rest